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Background: The use of perioperative thromboprophylaxis in urological surgery is
common but not standardized.
Objective: To characterize international practice variation in thromboprophylaxis use in
urological surgery.
Design, setting, and participants: We conducted a scenario-based survey addressing the
use of mechanical and pharmacological thromboprophylaxis in urological cancer pro-
cedures (radical cystectomy [RC], radical prostatectomy [RP], and radical nephrectomy
[RN]) among practicing urologists in Canada, Finland, and Japan. The survey presented
patient profiles reflecting a spectrum of risk for venous thromboembolism; the respon-
dents described their clinical practice.
Outcome measurements and statistical analysis: The proportion of respondents who
routinely used (1) mechanical, (2) pharmacological, and (3) extended pharmacological
prophylaxis was stratified by procedure. A logistic regression identified characteristics
associated with thromboprophylaxis use.
Results and limitations: Of 1051 urologists contacted, 570 (54%) participated in the
survey. Japanese urologists were less likely to prescribe pharmacological prophylaxis
than Canadian or Finnish urologists (p < 0.001 for all procedures). Canadian and Finnish
urologists exhibited large variation for extended pharmacological prophylaxis for RP and
RN. Finnish urologists were most likely to prescribe extended prophylaxis versus
Canadian and Japanese urologists (RC 98%, 84%, and 26%; Open RP 25%, 8%, and 3%;
robotic RP 11%, 9%, and 0%; and RN 43%, 7%, and 1%, respectively; p < 0.001 for each
procedure). Less variation was found regarding the prescription of mechanical prophy-
laxis, which was most commonly used until ambulation or discharge. The length of
hospital stay was longer in Japan and may bias estimates of extended prophylaxis in. Department of Urology, Helsinki University Hospital, Haartmaninkatu 4,
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Conclusions: We found large variation in clinical practice regarding pharmacological
thromboprophylaxis within and between countries. Knowledge translation of evi-
dence-based guidelines may reduce problematic international variation in practice.
Patient summary: Use of medications to decrease blood clots after urological cancer
surgery differs within and between countries. Closer adherence to urology guidelines
addressing the prevention of blood clots may decrease this variation and improve
patient outcomes.
© 2020 European Association of Urology. Published by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Table 1 – Scenarios tested in the survey with response options.
Scenario 1 (cystectomy): A 65-yr-old woman who has a BMI of 36 and a
personal history of VTE but is otherwise healthy is undergoing an open
radical cystectomy. If you were prescribing thromboprophylaxis for this
patient, what regimen would you choose most commonly?
Scenario 2 (prostatectomy): A 58-yr-old man with a BMI of 23 and no personal
or family history of VTE is undergoing a radical prostatectomy without
lymphadenectomy (respondents were asked to select an open or a robotic
approach). If you were prescribing thromboprophylaxis for this patient, what
regimen would you choose most commonly?
Scenario 3 (nephrectomy): An 80-yr-old man who has a BMI of 24 and no
personal or family history of VTE is undergoing an open radical
nephrectomy. If you were prescribing thromboprophylaxis for this patient,
what regimen would you choose most commonly?
Response options:
Pharmacological prophylaxis:
1. No pharmacological thromboprophylaxis
2. Pharmacological thromboprophylaxis until the patient is ambulating
3. Pharmacological thromboprophylaxis for the duration of hospital stay
4. Pharmacological thromboprophylaxis for the duration of hospital stay
and 2 wk after discharge
5. Pharmacological thromboprophylaxis for the duration of hospital stay
and >2 wk after discharge
Mechanical prophylaxis:
1. No mechanical thromboprophylaxis
2. Mechanical thromboprophylaxis until the patient is ambulating
3. Mechanical thromboprophylaxis for the duration of hospital stay
4. Mechanical thromboprophylaxis for the duration of hospital stay and 2
wk after discharge
5. Mechanical thromboprophylaxis for the duration of hospital stay and >2
wk after discharge
BMI = body mass index; VTE = venous thromboembolism.
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Venous thromboembolism (VTE), including deep vein
thrombosis and pulmonary embolism, represents a serious
and sometimes fatal complication of surgery [1]. Pharmaco-
logical prophylaxis decreases the relative risk of VTE in
surgical patients by approximately 50%, but with an
increase in the relative risk of postoperative major bleeding
of 50% [2]. Therefore, the decision to use pharmacological
prophylaxis presents a tradeoff between a reduction in VTE
and an increase in bleeding [3].
An additional challenge regarding the use of thrombo-
prophylaxis in urology is international clinical practice
variation [4–6]. A lack of knowledge of evidence regarding
the procedure- and patient-specific baseline risks of throm-
bosis and bleeding, critical in making an informed decision
on the use of thromboprophylaxis, may, at least in part,
explain this variation [1,2,7]. Conflicting recommendations
from different guidelines and previous lack of guidelines
specific to the different urological surgeries may also con-
tribute [3,8]. To further understand international variation
in thromboprophylaxis use in urological surgery, we con-
ducted an international survey (International Survey on Use
of Thromboprophylaxis in Urological Surgery [ISTHMUS]).
Our goal was to characterize the within- and between-
country variation in thromboprophylaxis use for common
urological procedures.
2. Patients and methods
2.1. Survey
We designed a questionnaire that consisted of three scenarios intended
to elicit practice in prescribing both pharmacological and mechanical
thromboprophylaxis for radical cystectomy (RC), open and robotic radi-
cal prostatectomy (RP), and radical nephrectomy (RN; Table 1). Using the
patient risk factor model used in the European Association of Urology
(EAU) guideline on thromboprophylaxis in urological surgery [3], the
survey presented brief patient profiles that reflected a spectrum of VTE
risks (Table 1). Table 2 presents the degree of VTE risk, based on
systematic reviews [2], associated with each scenario. This information
was not included in the survey and thus was unavailable to participants.
Participants indicated their usual practice for each patient profile using
response options consisting of single-answer multiple choices (Table 1).
Respondents also provided their age, gender, and urologist profile (resi-
dent/consultant). A group of clinicians and methodologists generated the
items in the questionnaire, which was then pilot tested and reviewed
with a group of 20 board-certified urological surgeons from Canada,
Finland, and Japan who assessed its face validity.Please cite this article in press as: Violette PD, et al. An Internati
Surgery. Eur Urol Focus (2020), https://doi.org/10.1016/j.euf.2020We performed this survey before the first procedure- and patient-
specific thromboprophylaxis guideline in urology—the EAU guideline—
was published [3]. We invited actively practicing urologists from Canada,
Finland, and Japan to complete the survey. In Canada, we invited Cana-
dian urologists attending the annual meeting of the Canadian Urological
Association (CUA), held in Ottawa in June 2015. In Finland and Japan, we
identified urologists from the registers of the Finnish Urological Associ-
ation and the Japanese Urological Association. In Canada, urologists
completed the survey at the conclusion of the plenary sessions and at
break periods throughout the conference. We collected surveys imme-
diately upon completion and used the number of urologists attending
the meeting as the denominator for calculating the response rate (the use
of the number of urologists attending the meeting as the denominator
likely underestimates the response rate). All urologists in Finland
received an invitation to participate by a postal letter. In Japan, a sample
of 500 urologists (of whom 487 proved to be eligible) were randomly
identified from the national membership directory and invited, by mail,
to participate. We mailed the questionnaires between August and Sep-
tember 2015 (first round), and mailed two rounds of reminders in
October (second round) and December 2015 (third round). Furthermore,onal Survey on the Use of Thromboprophylaxis in Urological
.05.015
Table 2 – VTE and major bleeding risk estimates of the presented patient profiles.
Scenario Operation Patient risk strataa Risk of VTE (%)b Risk of major bleeding (%)c
1 Open radical cystectomy High risk 11.6 0.3
2 Open radical prostatectomy without lymphadenectomy Low risk 1.0 0.1
2 Robotic radical prostatectomy without lymphadenectomy Low risk 0.2 0.4
3 Open radical nephrectomy Medium risk 2.2 0.1
VTE = venous thromboembolism.
a Patient risk stratification according to the European Association of Urology guideline on thromboprophylaxis in urological surgery [3].
b VTE defined as symptomatic pulmonary embolus or deep vein thrombosis within 30 d of surgery [2].
c Major bleeding defined as bleeding requiring reoperation within 30 d of surgery [2].
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upcoming mail survey.
In Canada, the CUA board of directors, who are independent of study
investigators, reviewed the proposal and approved the administration of
survey at the CUA annual meeting without requirement for further ethics
review. In Finland, the ethics committee of the Helsinki and Uusimaa
Hospital District granted exemption from ethical review (R11110). In
Japan, the ethics committee of the University of Fukui (Fukui, Japan;
#20150067) approved the protocol. The reporting of the study conforms
to the STROBE statement [9].
2.2. Statistical analysis
For every patient profile, we calculated the proportion of use of (1)
mechanical prophylaxis, (2) pharmacological prophylaxis, and (3)
extended pharmacological prophylaxis of 2 wk and tested for statistical
significance using chi-square analysis. As the length of hospital stay
varies substantially between countries (considerably longer in Japan
than in Canada or Finland; Supplementary Tables 1 and 2), and therefore
the implication of prophylaxis during hospital stay differs across jur-
isdictions (Supplementary material), definitions of extended prophylaxis
corresponded to duration of hospital stay in the three countries (Table 1
and Supplementary Table 3). We used multivariable logistic regression
adjusted for the included countries to determine whether the urologist
profile (resident/consultant) was associated with any mechanical pro-
phylaxis, any pharmacological prophylaxis, or extended prophylaxis. We
report the odds ratio and 95% confidence interval for the multivariable
logistic regression using a threshold p value of <0.05. All analyses were
performed in SPSS version 20 (IBM Corp., Armonk, NY, USA).
3. Results
The 570 urologists who participated in this survey (Table 3)
represent an overall response rate of 54% (Canada: 216 of
385, 57%; Finland: 110 of 179, 61%; and Japan: 244 of 487,
50%). Of the 570 eligible individuals who responded to the
survey, 566 (99%) responded to at least five out of sixTable 3 – Baseline characteristics of the respondents.
Canada Finla
Response (%) 216/385 (57) 110/1
Male (%) 194 (89.8) 91 (8
Female (%) 19 (8.8)a 19 (1
Age (yr), median (IQR) 38.0 (33–50) 48.0 
Consultant (%) 152 (70.4) 97 (8
Resident (%) 62 (28.7) 13 (1
IQR = interquartile range.
a Three missing values regarding gender in the Canadian sample.
Please cite this article in press as: Violette PD, et al. An Internati
Surgery. Eur Urol Focus (2020), https://doi.org/10.1016/j.euf.2020scenario questions. Most participants were men (89.6%
[511/570]); the median age of the participants was
43.0 yr (interquartile range: 35–54) with a majority being
consultants (82.5% [470/570]).
Almost all respondents used mechanical prophylaxis for
patients undergoing RC (Canada: 92% [199/216], Finland:
96% [106/110], Japan: 96% [234/244], p = 0.13; Table 4). More
respondents reported using mechanical prophylaxis after
an open RP in Japan (98% [239/244]) than in Finland (88%
[158/179]) and Canada (79% [171/216], p < 0.001). Similarly,
after a robotic RP, the Japanese urologists reported a higher
rate of mechanical prophylaxis (100%) than the Canadian
(81% [175/216]) and Finnish urologists (75% [83/110]; p <
0.001). Japanese urologists also reported more use of
mechanical prophylaxis after an RN (95% [232/244]) com-
pared with Canadian (84% [181/216]) and Finnish (80% [88/
110], p < 0.001).
Use of pharmacological prophylaxis of any duration after
RC was more common in Canada and Finland (both 99%
[208/210, 109/110]) than in Japan (70% [171/244], p < 0.001;
Table 4). Fewer Japanese respondents indicated that they
would use pharmacological prophylaxis after an RP (open
RP: 14% [34/244], robotic RP: 33% [81/244]) compared with
Canadian (open RP: 93% [201/216], robotic RP: 90% [194/
216]) and Finnish (open RP: 88% [97/110], robotic RP: 94%
[103/110]) respondents (p < 0.0001 for both open and
robotic RP). Similarly, more respondents reported using
pharmacological prophylaxis after an RN in Finland (95%
[105/110]) and Canada (92% [199/216]) than in Japan (20%
[49/244], p < 0.001).
Finnish and Canadian respondents were more likely to
use extended pharmacological prophylaxis after RC
(Finland: 98% [108/110], Canada: 84% [181/216]) than Japa-
nese respondents (26% [63/244], p < 0.001). It was uncom-
mon for respondents in any country to use extendednd Japan Total
79 (61) 244/487 (50) 570 (54)
2.7) 226 (92.6) 511 (89.6)
7.3) 18 (7.4) 56 (9.8)
(30–57.5) 45.0 (38–55) 43.0 (35–54)
8.2) 221 (90.6) 470 (82.5)
1.8) 22 (9.0) 97 (17.0)
onal Survey on the Use of Thromboprophylaxis in Urological
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Table 4 – Proportion (in percentages) of those with any duration of mechanical prophylaxis, any duration of pharmacological prophylaxis,
and pharmacological prophylaxis of at least 2 wk by procedure and country.
Open radical cystectomy Open radical prostatectomy









Canada 92 (87–95) 99 (96–100) 84 (78–88) 79 (70–86) 93 (86–97) 8 (4–15)
Finland 96 (89–98) 99 (94–100) 98 (93–100) 88 (67–97) 88 (67–97) 25 (11–47)
Japan 96 (93–98) 70 (61–73) 26 (21–32) 98 (92–99) 14 (9–22) 3 (1–8)
Robotic radical prostatectomy Open radical nephrectomy









Canada 81 (72–88) 90 (82–95) 9 (4–17) 80 (74–85) 92 (87–95) 7 (4–12)
Finland 75 (62–84) 94 (84–98) 11 (5–21) 84 (76–90) 95 (89–98) 43 (34–53)
Japan 100 (98–100) 33 (23–46) 0 (0–2) 95 (91–97) 20 (15–25) 1 (0–3)
CI = confidence interval.
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244], Canada: 8% [17/216], Finland: 25% [28/110]; p < 0001)
and robotic RP (Japan: 0% [0/244], Canada: 9% [19/216],
Finland: 11% [12/110]; p = 0.02). Finnish respondents (43%
[47/110]) were more likely to use extended pharmacological
prophylaxis after RN than Canadian (7% [15/216]) or Japa-
nese (1% [2/244]) respondents (p < 0.001).
Multivariable analysis, adjusted for the country, demon-
strated no difference in resident versus consultant urolo-
gists’ use of mechanical, pharmacological, or extended
pharmacological prophylaxis (Supplementary Table 4).
4. Discussion
This is the first study in urology to examine international
variability in the use of thromboprophylaxis between coun-
tries in different continents. This large-scale multinational
survey identified large variation in the use of pharmacolog-
ical VTE prophylaxis during hospital stay and in the use of
extended prophylaxis after discharge within and between
countries. Canadian and Finnish urologists reported similar
frequent use of pharmacological prophylaxis, but Japanese
respondents reported far less use. Reported use of mechan-
ical prophylaxis for urological procedures had much less
variation, both within and between countries. Finally, we
found no differences between resident and consultant urol-
ogists in the use of mechanical, pharmacological, or
extended pharmacological prophylaxis.
4.1. Strengths and limitations
The strengths of the current study include a population
representative of the target populations of Canadian,
Finnish, and Japanese urologists, in age and gender
distribution [10–12]. Our study’s strengths also include a
satisfactory participation rate and very high completenessPlease cite this article in press as: Violette PD, et al. An Internati
Surgery. Eur Urol Focus (2020), https://doi.org/10.1016/j.euf.2020of questionnaire responses. We assessed the use of throm-
boprophylaxis by clinical case scenarios relevant to current
clinical practice.
Our study has limitations. First, as this survey was
intended to capture an overview of practice pattern, we
are not able to draw conclusion about the causes of the
practice variation. We did not ask respondents about their
perception of the incidence of VTE—perception of a lower
risk in Japan could be responsible for a lower use of phar-
macological, but not mechanical, prophylaxis. Whether
such differences in incidence actually exist has not been
established [2]. Second, how urologists actually practice in a
hospital setting might differ from their responses to the
scenarios presented in our study. In addition, as thrombo-
prophylaxis is often prescribed by more junior doctors
rather than by the operating surgeon, we did not collect
data on the specialization of respondents. It is uncertain
whether this approach biased estimates. Third, we have
used different sampling strategies for Canada from those
used for Finland and Japan. This pragmatic decision was
based on our goal of including a representative sample in
each country. Fourth, many of the respondents do not
perform some of the procedures presented. They may,
however, still participate in the prescription of thrombo-
prophylaxis. Fifth, we assessed only a limited range of
surgeries and scenarios. Fifth, the length of hospital stay
was longer in Japan, which may influence the use of
extended prophylaxis. Finally, generalization to jurisdic-
tions beyond the three that we included in this survey
remains uncertain.
4.2. Comparison with other studies
There are few earlier surveys examining the use of periop-
erative VTE prophylaxis. A British survey [5], on a mixed
population of respondents including 29 consultantonal Survey on the Use of Thromboprophylaxis in Urological
.05.015
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cialists practicing in 64 UK pelvic cancer centers, found that
all units used low–molecular-weight heparin (LMWH) pro-
phylaxis routinely for the inpatient period after RC and 98%
used perioperative prophylaxis after RP. Routine use of
LMWH for all patients after discharge following RC was
reported in 67% and after RP in 61% of units (investigators
did not differentiate between approaches, such as open or
robotic) [5].
A US database study of 94 709 men who underwent RP
(72% open and 28% robotic) found that 52% of men after
open RP received mechanical only, 7% pharmacological only,
and 11% both mechanical and pharmacological prophylaxis,
and 30% received no prophylaxis [6]. Discharge prophylaxis
was not included in the scope of this study. Another US
study [4] surveyed the members of the American Urological
Association in 2011. Only 11% of those invited responded
(1210 respondents), of whom approximately 70% for RC and
<60% for RP reported the use of any thromboprophylaxis
“frequently” or “always” [4]. The authors did not address
postdischarge prophylaxis. Although small sample size [5],
retrospective database design [6], and low response rate [4]
limit the strength of inference from these studies, consis-
tent with our finding, there remains little doubt of consid-
erable variation in practice of thromboprophylaxis in uro-
logical procedures both within and between countries.
4.3. Implications of findings
The practice variation that we identified is likely due to
several factors. First, the quality of evidence supporting
decisions regarding VTE prophylaxis is not of high quality
and thus open to variable interpretation [2,13]. Second,
the low-quality evidence may also explain the divergent
recommendations from several major VTE guidelines in
different countries [8]. For instance, prominent VTE
guidelines from the American College of Chest Physicians
and National Institute for Health and Care Excellence do
not consider specific urological surgeries separately but
would consider all scenarios in the survey as “abdomino-
pelvic” [14,15]. Third, urologists in some regions may also
prefer to defer decisions regarding the use of thrombo-
prophylaxis to colleagues from other disciplines with a
different weighing of trade-off between bleeding and VTE
from a nonsurgeon point of view. Possibly, VTE risk may
also vary by population, given differences in body mass
index or age at surgery that may predominate in different
regions [14], with choices of prophylaxis appropriately
reflecting local risk.
We performed the survey prior to the publication of the
systematic reviews addressing estimates of absolute risks of
symptomatic VTE and major bleeding in urological surgery
[2,13] and an EAU guideline addressing thromboprophylaxis
[3], the first procedure and patient risk factor–specific
guideline in urology. Therefore, respondents could not have
been influenced by these guideline recommendations, and
this survey can be used as a benchmark for tracking changes
in practice pattern with further dissemination of urology-
specific VTE guidelines. Healthcare professionals acrossPlease cite this article in press as: Violette PD, et al. An Internati
Surgery. Eur Urol Focus (2020), https://doi.org/10.1016/j.euf.2020jurisdictions may consider, in their clinical decision making,
this evidence-based, procedure-specific guideline [3],
which has also been published as a freely available info-
graphic [15]. Doing so would rationalize the practice and
may decrease this substantial variation.
In patients at high risk of VTE, for some major surgeries,
there is a clear net benefit to extended pharmacological
thromboprophylaxis [2,3,16]. Our results suggest that for
high-risk VTE and low bleeding risk (scenario 1: cystectomy
for high-risk patients, Tables 1 and 2), practice in Canada
and Finland follows the EAU guideline more closely [3].
In scenario 2 (RP without lymphadenectomy for low-
risk patients; Tables 1 and 2), the EAU guideline suggests
the use of extended pharmacological prophylaxis in the
open approach but recommends against the use of pro-
phylaxis in robotic prostatectomy without lymphadenec-
tomy [3]. In our survey, participants from Canada and
Finland typically reported the use of pharmacological pro-
phylaxis in hospital but not after discharge irrespective of
the approach (open vs robotic), whereas one in seven of
Japanese urologists after an open approach and one in
three after a robotic approach reported in-hospital use
of pharmacological prophylaxis.
In scenario 3 (open RN for medium-risk patients;
Tables 1 and 2), respondents’ practice in this situation
proved to be less aligned with EAU guideline recommenda-
tions [3]: Canadian and Finnish respondents tended to
report the use of in-hospital prophylaxis but not discharge
prophylaxis, while Japanese respondents typically did not
report any use of pharmacological prophylaxis.
4.4. Unanswered questions and future research
Variation in practice suggests limited adherence to clinical
guidelines, which should represent the best practice for
most patients. Therefore, efforts to increase familiarity with
EAU guidelines [3]— rigorously evidence-based and the first
procedure-specific guideline—may improve patient care.
Perioperative VTE guidelines depend on a clear understand-
ing of patient-important trade-offs and the quality of sup-
porting evidence. Therefore, future efforts to improve the
body of evidence, especially with the conduct of high-
quality trials and observational studies, will result in
improved clinical guidance and patient care [3,17,18]. In
addition, future surveys are needed to monitor changes
in practice regarding perioperative thromboprophylaxis
resulting from publication of new guidance.
5. Conclusions
We performed a large-scale multinational survey and iden-
tified a large variation in the use of pharmacological VTE
prophylaxis within and between countries. This variation
existed in the use of both pharmacological prophylaxis
during hospital stay and extended prophylaxis after dis-
charge. The variation in the reported use of mechanical
prophylaxis for urological procedures was much less, with
uniformly high use over 75% across all scenarios. Knowledge
translation of evidence-based guidelines may reduceonal Survey on the Use of Thromboprophylaxis in Urological
.05.015
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EUF-927; No. of Pages 6problematic variation in practice globally and thus may help
optimize future patient care.
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